Twin Focus Capital Partners, LLC Incyte Corp Transaction History

Twin Focus Capital Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $170,234 - $213,134	2,534 New	2,534 $203,000
Q2 2022 Aug 15, 2022	SELL	$66.18 - $83.18 $168,957 - $212,358	-2,553 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $168,549 - $203,499	2,553 New	2,553 $203,000
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $174,421 - $213,410	-2,540 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $2,715 - $2,976	34 Added 1.36%	2,540 $214,000
Q2 2020 Aug 12, 2020	BUY	$74.18 - $108.93 $185,895 - $272,978	2,506 New	2,506 $261,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $157,950 - $214,925	-2,500 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$73.04 - $95.72 $182,600 - $239,300	2,500 New	2,500 $218,000
Q3 2019 Nov 07, 2019	SELL	$72.82 - $86.52 $182,049 - $216,300	-2,500 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $183,800 - $221,750	2,500 New	2,500 $212,000
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $152,125 - $209,950	-2,500 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $272,875 - $345,675	2,500	2,500 $292,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.